Mark Sabag - Mar 5, 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, International Markets
Signature
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Stock symbol
TEVA
Transactions as of
Mar 5, 2024
Transactions value $
-$1,352,090
Form type
4
Date filed
3/7/2024, 04:12 PM
Previous filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +23.8K +5.93% 424K Mar 5, 2024 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +58.1K +13.7% 483K Mar 5, 2024 Direct F1, F2
transaction TEVA Ordinary Shares Sale -$1.35M -100K -20.72% $13.52 383K Mar 5, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -23.8K -50% $0.00 23.8K Mar 5, 2024 Ordinary Shares 23.8K Direct F1, F2, F4
transaction TEVA Restricted Share Units Options Exercise $0 -58.1K -100% $0.00* 0 Mar 5, 2024 Ordinary Shares 58.1K Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.
F5 Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.